RxDoctor Payments Data

Jeffrey Gray, MD

Psychiatry · Sacramento, CANPI 1033478748

Payments from drug & device makers

$4,499in general payments, 2019–2025

Across 203 payments — averaging $22.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$821
  • Neurocrine Biosciences, Inc.$570
  • Teva Pharmaceuticals USA, Inc.$569
  • AbbVie$306
  • Alkermes, Inc.$193
  • plus $213 from 6 others

What the payments were for

  • Food & beverage$4,45299%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,499 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$18,220
Medicare patients
29
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole61$97,248
CaplytaLumateperone Tosylate41$63,916
TrintellixVortioxetine Hydrobromide87$44,694
LybalviOlanzapine/Samidorphan Malate17$28,518
VraylarCariprazine Hcl14$19,707
Methylphenidate ErMethylphenidate Hcl13$4,020
Quetiapine Fumarate107$2,490
Venlafaxine Hcl ErVenlafaxine Hcl11$1,856
Olanzapine11$1,116
Doxepin Hcl14$655
Desvenlafaxine Succinate ErDesvenlafaxine Succinate16$623
Lithium Carbonate ErLithium Carbonate30$611
Guanfacine Hcl ErGuanfacine Hcl22$575
Sertraline Hcl137$452
Bupropion XlBupropion Hcl35$447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$63$97,24861 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$821$63,91641 claims
Alkermes, Inc.Lybalvi$193$28,51817 claims
AbbVieVraylar$306$19,70714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →